These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36566165)

  • 21. Role of Metrology in Axial Spondyloarthritis: Does It Provide Unique Information in Assessing Patients and Predicting Outcome? Results From the British Society for Rheumatology Biologic Register for Ankylosing Spondylitis.
    Biallas RL; Dean LE; Davidson L; Hollick R; Pathan E; Robertson L; Jones GT; Macfarlane GJ; Rotariu O
    Arthritis Care Res (Hoboken); 2022 Apr; 74(4):665-674. PubMed ID: 33140891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis.
    Armağan B; Kılıç L; Farisoğulları B; Yardımcı GK; Bilgin E; Bölek EÇ; Karadağ Ö; Bilgen ŞA; Kiraz S; Ertenli İ; Kalyoncu U
    Rheumatol Int; 2023 Jan; 43(1):147-156. PubMed ID: 36129541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?
    Atzeni F; Siragusano C; Masala IF; Antonio C; Valentina P; D'Angelo S
    Expert Opin Biol Ther; 2022 Jul; 22(7):843-853. PubMed ID: 35722768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort.
    Ciurea A; Kissling S; Bürki K; Baraliakos X; de Hooge M; Hebeisen M; Papagiannoulis E; Exer P; Bräm R; Nissen MJ; Möller B; Kyburz D; Andor M; Distler O; Scherer A; Micheroli R
    RMD Open; 2022 Feb; 8(1):. PubMed ID: 35110365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years.
    van der Heijde D; Østergaard M; Reveille JD; Baraliakos X; Kronbergs A; Sandoval DM; Li X; Carlier H; Adams DH; Maksymowych WP
    J Rheumatol; 2022 Mar; 49(3):265-273. PubMed ID: 34853086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature.
    Rocha FAC; Pinto ACMD; Lopes JR; Deodhar A
    Clin Rheumatol; 2021 May; 40(5):1881-1887. PubMed ID: 33230684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to: 'Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli
    Ciurea A; Micheroli R
    Ann Rheum Dis; 2022 Nov; 81(11):e227. PubMed ID: 32933922
    [No Abstract]   [Full Text] [Related]  

  • 28. [Use of TNF inhibition therapy in patients with axial spondyloarthritis].
    Kiltz U
    Z Rheumatol; 2015 Apr; 74(3):263-4. PubMed ID: 25518965
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J; Sieper J; Weiß A; Zink A; Listing J
    Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ASAS-OMERACT core domain set for axial spondyloarthritis.
    Navarro-Compán V; Boel A; Boonen A; Mease P; Landewé R; Kiltz U; Dougados M; Baraliakos X; Bautista-Molano W; Carlier H; Chiowchanwisawakit P; Dagfinrud H; de Peyrecave N; El-Zorkany B; Fallon L; Gaffney K; Garrido-Cumbrera M; Gensler LS; Haroon N; Kwan YH; Machado PM; Maksymowych WP; Poddubnyy D; Protopopov M; Ramiro S; Shea B; Song IH; van Weely S; van der Heijde D
    Semin Arthritis Rheum; 2021 Dec; 51(6):1342-1349. PubMed ID: 34489113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in treatment of axial spondyloarthritis are associated with improved patient outcomes: data from the Ankylosing Spondylitis Registry of Ireland (ASRI).
    Maguire S; Fitzgerald G; Gallagher P; O'Shea F
    Rheumatol Int; 2022 May; 42(5):831-838. PubMed ID: 35088133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
    Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
    J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of active inflammation, chronic structural damage, and response to treatment of sacroiliitis in axial spondyloarthritis using the Spondyloarthritis research consortium of Canada scoring system.
    Zhang Y; Guo Z; Zhan Y; Qu J; Lei X
    BMC Musculoskelet Disord; 2022 Jul; 23(1):654. PubMed ID: 35804360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of non-radiographic axial spondyloarthritis: it is only the beginning.
    van der Horst-Bruinsma IE
    Ann Rheum Dis; 2013 Jun; 72(6):789-90. PubMed ID: 23667168
    [No Abstract]   [Full Text] [Related]  

  • 35. Is the Difficult-to-Treat (D2T) concept applicable to axial spondyloarthritis?
    Wendling D; Verhoeven F; Prati C
    Joint Bone Spine; 2023 May; 90(3):105512. PubMed ID: 36528335
    [No Abstract]   [Full Text] [Related]  

  • 36. Therapeutic considerations in spondyloarthritis patients who fail tumour necrosis factor antagonists.
    Ritchlin CT
    Best Pract Res Clin Rheumatol; 2010 Oct; 24(5):683-92. PubMed ID: 21035088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.
    Poddubnyy D; Rudwaleit M
    Expert Opin Biol Ther; 2013 Nov; 13(11):1599-611. PubMed ID: 24074224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.
    Sieper J; Rudwaleit M; Lenaerts J; Wollenhaupt J; Myasoutova L; Park SH; Song YW; Yao R; Huyck S; Govoni M; Chitkara D; Vastesaeger N
    Rheumatology (Oxford); 2016 Nov; 55(11):1946-1953. PubMed ID: 27411482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Axial spondyloarthritis: emerging drug targets.
    Cherqaoui B; Araujo LM; Glatigny S; Breban M
    Expert Opin Ther Targets; 2021 Aug; 25(8):633-644. PubMed ID: 34431431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.
    Poddubnyy D; Gensler LS
    Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):807-18. PubMed ID: 25488786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.